Mode
Text Size
Log in / Sign up
Phase 2 Completed N=128 Treatment

A Study of Talazoparib in Men With DNA Repair Defects and Metastatic Castration-Resistant Prostate Cancer

Source: ClinicalTrials.gov NCT03148795 ↗
Enrolled (actual)
128
Serious AEs
40.2%
Results posted
Sep 2021
Primary outcomePrimary: Best Objective Response Rate (ORR) — 29.8 Percentage of participants

Summary

The purpose of this international, phase 2, open-label, response rate study of talazoparib is to assess the efficacy and safety of talazoparib in men with DNA repair defects metastatic castration-resistant prostate cancer (CRPC) who previously received taxane-based chemotherapy and progressed on at least 1 novel hormonal agent (enzalutamide and/or abiraterone acetate/prednisone).

Outcome Measures

OutcomeResultp-value
PRIMARY
Best Objective Response Rate (ORR)
29.8
SECONDARY
Time to Objective Response
3.4
SECONDARY
Duration of Response (DOR)
12.8
SECONDARY
Percentage of Participants With Prostate-Specific Antigen (PSA) Response of Greater Than or Equal to (>=) 50 Percentage (%)
45.8
SECONDARY
Percentage of Participants With Conversion of Circulating Tumor Cell (CTC) Count
63.6
SECONDARY
Percentage of Participants With a Null CTC Count
53.3
SECONDARY
Percentage of Participants With Baseline CTC Count <5 CTC Showed Increased CTC Counts at Any Time on Study
37.9
SECONDARY
Time to Prostate-Specific Antigen (PSA) Progression
9.2
SECONDARY
Radiographic Progression-Free Survival (PFS)
5.6
SECONDARY
Overall Survival (OS)
16.9
SECONDARY
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
125
SECONDARY
Number of Participants With Permanent Treatment Discontinuation Due to Adverse Events
21
SECONDARY
Number of Participants With Clinically Significant Abnormalities in Vital Signs
0; 0; 0; 0; 17; 0
SECONDARY
Number of Participants With Shift in Laboratory Parameter Values (Hematology) From Grade Less Than Equal to (<=) 2 at Baseline to Grade 3 or 4 Post-baseline
30; 1; 23; 0; 11; 3
SECONDARY
Number of Participants With Shift in Laboratory Parameter Values (Chemistry) From Grade <=2 at Baseline to Grade 3 or 4 Post-baseline
0; 9; 0; 0; 2; 1
SECONDARY
Number of Participants With Dose Modification
37
SECONDARY
Time to Deterioration in Pain Symptom Scores
NA
SECONDARY
Change From Baseline in Participant Reported Pain Scores Per BPI-SF Question 3
-0.51; -1.39; -1.20; -1.25; -0.85; -1.06
SECONDARY
Change From Baseline in European Quality of Life 5-Domain 5-Level Scale (EQ-5D-5L) Visual Analogue Scores (VAS)
4.16; 4.44; 6.61; 6.18; 7.68; 7.84
SECONDARY
Number of Participants With 5 Response Levels for EQ-5D-5L Mobility Domain
30; 29; 25; 12; 0; 36
SECONDARY
Number of Participants With 5 Response Levels for EQ-5D-5L Self-Care Domain
65; 18; 9; 3; 0; 63
SECONDARY
Number of Participants With 5 Response Levels for EQ-5D-5L Usual Activity Domain
33; 30; 19; 10; 4; 33
SECONDARY
Number of Participants With 5 Response Levels for EQ-5D-5L Pain and Discomfort Domain
15; 35; 30; 16; 0; 25
SECONDARY
Number of Participants With 5 Response Levels for EQ-5D-5L Anxiety and Depression Domain
48; 30; 18; 0; 0; 45
SECONDARY
Pre-dose Plasma Concentration (Ctrough) of Talazoparib
2631.898; 4748.147; 4213.250; 4378.123
SECONDARY
Post-dose Plasma Concentration (Ctrough) of Talazoparib
2289.540; 10713.918

Eligibility Criteria

Inclusion Criteria

  • At least 18 years of age.
  • Histologically or cytologically confirmed adenocarcinoma of the prostate without signet cell, or small cell features.
  • Patients must have measurable soft tissue disease per RECIST 1.1
  • DNA damage repair deficiency as assessed centrally by a gene mutation biomarker panel (testing of de novo or archival tumor tissue (via central laboratory) or prior historical testing (with Sponsor approval) using the Foundation Medicine, FoundationOne CDx™ NGS gene panel test.
  • Consent to a saliva sample collection for a germline comparator, unless prohibited by local regulations or ethics committee (EC) decision.
  • Serum testosterone ≤ 1.73 nmol/L (50 ng/dL) at screening.
  • Bilateral orchiectomy or ongoing androgen deprivation therapy with a gonadotropin-releasing hormone (GnRH) agonist/antagonist (surgical or medical castration).
  • Progressive disease at study entry defined as 1 or more of the following 3 criteria:
  • A minimum of 3 rising PSA values with an interval of at least 1 week between determinations. The screening central laboratory PSA value must be ≥ 2 μg/L (2 ng/mL) if qualifying solely by PSA progression.
  • Soft tissue disease progression as defined by RECIST 1.1.
  • Bone disease progression defined by PCWG3 with 2 or more new metastatic lesions on bone scan.
  • Metastatic disease.
  • Previous treatment with 1 or 2 chemotherapy regimens including at least 1 taxane-based regimen for metastatic (non castrate or castrate) prostate cancer. Patients may have received radium-223 and/or cabazitaxel, or were deemed unsuitable, declined, or did not have access to these therapies.
  • Documented disease progression (either radiographic or biochemical) on at least 1 novel hormonal therapy (enzalutamide and/or abiraterone acetate/prednisone) for the treatment of metastatic CRPC, irrespective of prior NHT treatment for non castrate prostate cancer or nonmetastatic (M0) CRPC.
  • Bisphosphonate or denosumab dosage must have been stable for at least 4 weeks before day 1 for patients receiving these therapies.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.
  • Estimated life expectancy of ≥ 6 months as assessed by the investigator.
  • Able to swallow the study drug, have no known intolerance to study drugs or excipients, and comply with study requirements.
  • Must use a condom when having sex from the time of the first dose of study drug through 4 months after last dose of study drug. A highly effective form of contraception must be used from the time of the first dose of study drug through 4 months after last dose of study drug when having sex with a non pregnant female partner of childbearing potential.
  • Must agree not to donate sperm from the first dose of study drug to 4 months after the last dose of study drug.
  • Patients must be willing and able to comply with scheduled visits, treatment plan, laboratory tests and other study procedures.

Exclusion Criteria

  • 1. Use of systemic chemotherapeutic (including but not limited to taxanes), hormonal, biologic, or radionuclide therapy for treatment of metastatic prostate cancer (other than approved bone targeting agents and GnRH agonist/antagonist) or any other investigational agent within 4 weeks before day 1.
  • Prior treatment with a PARP inhibitor, cyclophosphamide, or mitoxantrone chemotherapy. Patients who discontinued prior platinum based chemotherapy <=6 months prior to screening or whose disease previously progressed on platinum based therapy at any time in the past are also excluded.
  • Treatment with any concurrent cytotoxic chemotherapy or investigational drug(s) within 4 weeks or 5 half lives of the drug (whichever is longer) before Day 1 and/or during study participation
  • Radiation therapy within 3 weeks (within 2 weeks, if single fraction of radiotherapy) before day 1.
  • Major surgery within 2 weeks before day 1.
  • Clinically significant cardiovascular disease.
  • Significant ren
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03148795). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search